XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Variable Interest Entity
9 Months Ended
Sep. 30, 2024
Variable Interest Entity, Measure of Activity [Abstract]  
Variable Interest Entity

Note 9—Variable Interest Entity

In July 2021, we entered into an agreement whereby we obtained an 80.2% interest in DomaniRx, LLC (DomaniRx), a variable interest entity under GAAP. We have the power to direct the majority of the activities of DomaniRx that most significantly impact its economic performance, the obligation to absorb losses and the right to receive benefits from DomaniRx. Accordingly, we determined that we are the primary beneficiary of DomaniRx and consolidate its results.

During the three months ended September 30, 2024, the Board of DomaniRx authorized a mandatory additional capital contribution in accordance with each member’s ownership interest in DomaniRx in the amount of $75.0 million. Our cash capital contribution during the three months ended September 30, 2024 was $60.2 million.

The carrying value of the assets and liabilities associated with DomaniRx included in our condensed consolidated balance sheet at September 30, 2024 and December 31, 2023, which are limited for use in its operations and do not have recourse against our general credit or our senior secured credit facilities, are as follows:

 

 

September 30,

 

December 31,

 

 

 

2024

 

2023

 

Assets:

 

 

 

 

 

Cash and cash equivalents

 

$

159.0

 

$

100.2

 

Intangible assets

 

 

213.2

 

 

193.3

 

Other assets

 

 

2.1

 

 

3.2

 

Liabilities:

 

 

 

 

 

Other liabilities

 

 

1.3

 

 

3.9